Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 14,109 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 2 Interventional Results available

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419506
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 29, 2026, 5:08 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 29, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463
View directory record Official record
Conditions
Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo
Biological · Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Not listed Phase 3 Interventional

Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization

NCT00438867
View directory record Official record
Conditions
Angina Pectoris
Interventions
Ad5FGF-4, Placebo
Genetic
Lead sponsor
Cardium Therapeutics
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

NCT06031844
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
DFV890, DFV890 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma

NCT01898598
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Placebo, Vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 29, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

NCT07523581
View directory record Official record
Conditions
Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Interventions
Exaluren
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

NCT00282464
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Geodon (Ziprasidone)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
43
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 29, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487
View directory record Official record
Conditions
Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Interventions
PALI-2108, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Sun City, Arizona • San Diego, California • Bristol, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Active, not recruiting Phase 3 Interventional

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793
View directory record Official record
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT01106014
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
43
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 29, 2026, 5:08 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

NCT06484114
View directory record Official record
Conditions
Obesity, Weight Change Trajectory, Weight Change, Body
Interventions
Revita Duodenal Mucosal Resurfacing (DMR), Sham
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4

NCT01900704
View directory record Official record
Conditions
Nocturia
Interventions
SER120 750 ng, SER120 1500 ng, Placebo
Drug
Lead sponsor
Serenity Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT01430312
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02431312
View directory record Official record
Conditions
Hepatitis B
Interventions
INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
Biological · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

NCT00565812
View directory record Official record
Conditions
Osteoarthritis
Interventions
SD-6010, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 99 Years
Enrollment
1,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
120
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 29, 2026, 5:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

NCT06741228
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

NCT01732536
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyps
Interventions
S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray
Drug · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Atherton, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 29, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00996164
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 5:08 AM EDT